Home / Products / Polyclonal antibody /

LRRK2 Polyclonal Antibody

Product code: YP-Ab-06735
Promotional price:

Product introduction

Reactive species
Human;Mouse
Applications
IHC;IF
Antibody type
Polyclonal Antibody
Gene Name
LRRK2 PARK8
Protein name
Leucine-rich repeat serine/threonine-protein kinase 2 (EC 2.7.11.1) (Dardarin)
Dalton(DA)
277kD
Immunogen
Synthesized peptide derived from part region of human protein
Specificity
LRRK2 Polyclonal Antibody detects endogenous levels of protein.
Constitute
Liquid in PBS containing 50% glycerol, and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
IHC-p 1:50-300. IF 1:50-200
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Stockpile
-20°C/1 year
Other name
Background
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008],
Function
catalytic activity:ATP + a protein = ADP + a phosphoprotein.,disease:Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8) [MIM:607060, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulati

Open

Product Details

Customer data and reviews (0)

Fold content

Citation

Fold content

Experimental scheme

Fold content
>